Editing Non-Hodgkin lymphoma (section)

==Treatment==
Treatment depends on whether the lymphoma is slow or fast growing and if it is in one area or many areas.<ref name="NCI2016AdPt" /> Treatments may include [[chemotherapy]], [[radiation therapy|radiation]], [[immunotherapy]], [[targeted therapy]], [[hematopoietic stem cell transplantation|stem-cell transplantation]], surgery, or [[watchful waiting]].<ref name="NCI2016AdPt" /> If the blood becomes overly thick due to high numbers of [[antibodies]], [[plasmapheresis]] may be used.<ref name="NCI2016AdPt" /> Radiation and some chemotherapy, however, increase the risk of other cancers, [[heart disease]], or nerve problems over the subsequent decades.<ref name="NCI2016AdPt" />

The traditional treatment of NHL includes [[chemotherapy]], [[radiotherapy]], and [[Stem cell transplant|stem-cell transplants]].<ref>{{cite web|url=https://www.cancer.org.au/about-cancer/types-of-cancer/lymphoma/non-hodgkin-lymphoma.html|title=Non-Hodgkin lymphoma|publisher=Cancer Council Australia|date=22 March 2019|access-date=23 August 2019|archive-date=23 August 2019|archive-url=https://web.archive.org/web/20190823035616/https://www.cancer.org.au/about-cancer/types-of-cancer/lymphoma/non-hodgkin-lymphoma.html|url-status=dead}}</ref><ref>{{cite web|url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/new-research.html|title=Non-Hodgkin Lymphoma Treatment|publisher=American Cancer Society|date=2019|access-date=23 August 2019}}</ref> There have also been developments in [[immunotherapy]] used in the treatment of NHL.<ref>{{cite web|url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/immunotherapy.html|title=Immunotherapy for Non-Hodgkin Lymphoma|publisher=American Cancer Society|date=2019|access-date=23 August 2019}}</ref>

=== Chemotherapy ===
The most common chemotherapy used for B-cell non-Hodgkin lymphoma is [[R-CHOP]], which is a regimen of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab.<ref>{{cite web|url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/b-cell-lymphoma.html|title=Treating B-Cell Non-Hodgkin Lymphoma|publisher=American Cancer Society|date=2019|access-date=23 August 2019}}</ref>

R-CHP with [[polatuzumab vedotin]], an antibody-drug conjugate, was included as a category 1 preferred regimen for first-line DLBCL by the National Comprehensive Cancer Network in 2023.<ref>{{cite web |title=With hard-fought Polivy approval, Roche looks to shake up decades of established practice in lymphoma |url=https://www.fiercepharma.com/pharma/roche-wins-hard-fought-fda-approval-polivy-changing-20-years-lymphoma-practice |publisher=Fierce Pharma}}</ref>

=== Treatment complications ===
If participants receive stem-cell transplants, they can develop a [[graft-versus-host disease]]. When compared with placebo for treating immune mediated inflammation post transplantation and in autoimmunity, mesenchymal stromal cells (MSCs) may reduce the all-cause mortality if they are used for a therapeutic reason.<ref name=":0" /> Moreover, the therapeutic use of MSCs may increase the complete response of acute and chronic GvHD, but the evidence is very uncertain.<ref name=":0" /> The evidence suggests that MSCs for prophylactic reason result in little to no difference in the all-cause mortality, in the relapse of malignant diseases, and in the incidence of acute GvHD.<ref name=":0" /> The evidence suggests that MSCs for prophylactic reason reduce the incidence of chronic GvHD.<ref name=":0">{{cite journal | vauthors = Fisher SA, Cutler A, Doree C, Brunskill SJ, Stanworth SJ, Navarrete C, Girdlestone J | title = Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD009768 | date = January 2019 | issue = 1 | pmid = 30697701 | doi = 10.1002/14651858.CD009768.pub2 | collaboration = Cochrane Haematological Malignancies Group | pmc = 6353308 }}</ref>

[[Platelet transfusion]]s may be necessary for those who receive chemotherapy or undergo a stem cell transplantation due to the higher risk for bleeding. When comparing therapeutic/non-prophylactic platelet transfusions to prophylactic platelet transfusions there is little to no difference in the mortality secondary to bleeding and they may result in a slight reduction in the number of days on which a significant bleeding event occurred.<ref name=":1">{{cite journal|vauthors=Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A, Heddle N|date=May 2012|title=Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation|journal=The Cochrane Database of Systematic Reviews|issue=5|pages=CD004269|doi=10.1002/14651858.CD004269.pub3|pmid=22592695|collaboration=Cochrane Haematological Malignancies Group}}</ref> The evidence suggests that therapeutic platelet transfusions result in a large increase in the number of people with at least one significant bleeding event and they likely result in a large reduction in the number of platelet transfusions.<ref name=":1" /><ref>{{cite journal | vauthors = Estcourt LJ, Stanworth SJ, Doree C, Hopewell S, Trivella M, Murphy MF | title = Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation | journal = The Cochrane Database of Systematic Reviews | issue = 11 | pages = CD010983 | date = November 2015 | volume = 2015 | pmid = 26576687 | pmc = 4717525 | doi = 10.1002/14651858.CD010983.pub2 | collaboration = Cochrane Haematological Malignancies Group }}</ref>

=== Other ===
It is unclear if including aerobic physical exercise, in addition to the standard treatment for adult patients with haematological malignancies, is effective at reducing anxiety and serious adverse effects.<ref name=":2" /> Aerobic physical exercises may result in little to no difference in the mortality, in the quality of life and in the physical functioning.<ref name=":2" /> These exercises may result in a slight reduction in depression and most likely reduce fatigue.<ref name=":2">{{cite journal | vauthors = Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N | title = Aerobic physical exercise for adult patients with haematological malignancies | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD009075 | date = January 2019 | issue = 1 | pmid = 30702150 | doi = 10.1002/14651858.CD009075.pub3 | collaboration = Cochrane Haematological Malignancies Group | pmc = 6354325 }}</ref>